Article

CURE Inaugural Commercial to Air During SU2C Telecast

CURE Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, will launch its first television commercial featuring curetoday.com during the Stand Up To Cancer (SU2C) telecast tonight.

CURE Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, will launch its first television commercial featuring curetoday.com during the Stand Up To Cancer (SU2C) telecast tonight, announced Michael J. Hennessy Jr., president of MJH Associates, Inc., parent company of CURE Media Group. The commercial aims to give individuals with cancer a platform to voice how they are more than just patients.

“We are so honored to be recognized during the Stand Up To Cancer (SU2C) telecast,” said Michael J. Hennessy Jr., in making the announcement. “This is a huge achievement for the CURE Media Group and we are so thankful to get our message across airing our first commercial.”

CURE® message, “Today, I’m more than a patient,” will fill millions of screens during SU2C’s sixth biennial televised fundraising special. CURE® hopes viewers will share how they are more than a patient, using the hashtag #MoreThanAPatient on social media.

The commercial will air on CBS in New York, San Francisco and Boston on Friday, Sept. 7 at 8 p.m. ET/PT and 7 p.m. CT.

To see the commercial after it airs, visit http://www.curetoday.com or find us on Twitter @cure_magazine, Facebook @curemagazine or Instagram @curetoday.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of man.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Related Content